Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $90.17.

ITCI has been the topic of a number of recent research reports. The Goldman Sachs Group upped their target price on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 17th. Robert W. Baird raised their price objective on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Mizuho increased their price target on shares of Intra-Cellular Therapies from $82.00 to $96.00 and gave the stock a “buy” rating in a report on Monday, April 22nd. TD Cowen lifted their price objective on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $120.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 24th.

Intra-Cellular Therapies Trading Down 5.9 %

Shares of NASDAQ ITCI opened at $67.00 on Thursday. The company has a 50 day simple moving average of $69.03 and a two-hundred day simple moving average of $65.86. The stock has a market cap of $6.49 billion, a price-to-earnings ratio of -45.89 and a beta of 1.01. Intra-Cellular Therapies has a 12 month low of $45.50 and a 12 month high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $144.90 million during the quarter, compared to the consensus estimate of $141.41 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The firm’s quarterly revenue was up 52.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.46) earnings per share. Analysts forecast that Intra-Cellular Therapies will post -0.59 EPS for the current year.

Insider Transactions at Intra-Cellular Therapies

In related news, Director Joel S. Marcus sold 26,328 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $68.68, for a total value of $1,808,207.04. Following the completion of the transaction, the director now directly owns 39,662 shares of the company’s stock, valued at approximately $2,723,986.16. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Intra-Cellular Therapies news, Director Joel S. Marcus sold 26,328 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $68.68, for a total value of $1,808,207.04. Following the transaction, the director now directly owns 39,662 shares of the company’s stock, valued at approximately $2,723,986.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Suresh K. Durgam sold 6,450 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total value of $429,312.00. Following the completion of the sale, the executive vice president now owns 16,170 shares of the company’s stock, valued at $1,076,275.20. The disclosure for this sale can be found here. Insiders have sold 168,487 shares of company stock valued at $11,364,950 over the last ninety days. Insiders own 3.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ITCI. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in Intra-Cellular Therapies during the first quarter worth about $18,379,000. ProShare Advisors LLC increased its holdings in shares of Intra-Cellular Therapies by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 23,621 shares of the biopharmaceutical company’s stock worth $1,635,000 after buying an additional 1,962 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Intra-Cellular Therapies by 232.0% during the 1st quarter. Russell Investments Group Ltd. now owns 50,845 shares of the biopharmaceutical company’s stock valued at $3,519,000 after buying an additional 35,528 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Intra-Cellular Therapies during the 1st quarter valued at approximately $32,000. Finally, Sei Investments Co. lifted its holdings in Intra-Cellular Therapies by 9.8% in the first quarter. Sei Investments Co. now owns 128,311 shares of the biopharmaceutical company’s stock valued at $8,880,000 after acquiring an additional 11,488 shares during the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.